Combination Treatment with Sonrotoclax (BGB-11417), a Second-Generation BCL2 Inhibitor, and Zanubrutinib, a Bruton Tyrosine Kinase (BTK) Inhibitor, Is Well Tolerated and Achieves Deep Responses in Patients with Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (TN-CLL/SLL): Data from an Ongoing Phase 1/2 Study-MedSci.cn

Combination Treatment with Sonrotoclax (BGB-11417), a Second-Generation BCL2 Inhibitor, and Zanubrutinib, a Bruton Tyrosine Kinase (BTK) Inhibitor, Is Well Tolerated and Achieves Deep Responses in Patients with Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (TN-CLL/SLL): Data from an Ongoing Phase 1/2 Study

Tam, CS; Anderson, MA; Lasica, M; Verner, E; Opat, SS; Ma, S; Weinkove, R; Cordoba, R; Soumerai, J; Ghia, P; Leitch, S; Hilger, J; Fang, YQ; Simpson, D; Guo, HY; Cheah, CY

BLOOD, 2023; 142 ():

科室
- - 订阅+
  - 更多科室
工具
服务